The Toronto-based biotech company, which is investigating new psychedelic drugs as a treatment for Alzheimer’s disease, recently received approval from Argentine regulators to initiate Phase II clinical trials of its new psychedelic compound, BMND08. It mentions that it has obtained approval to do so.
“As we continue our efforts to identify indications that can provide significant improvements for patients struggling with mental health, we are pleased to announce the approval of the BMND08 new drug candidate for a Phase II clinical trial. To work on a new line of development for alleviating depression and anxiety conditions, we are said in a statement from the company.
Biomind Labs is a biotechnology research and development company, researching new drugs and innovative nanotechnology delivery systems for a variety of psychiatric and neurological conditions. The company uses its technology to develop new pharmaceutical formulations of key psychedelic molecules, N,N-dimethyltryptamine, 5-MeO-DMT, and mescaline. A breakthrough treatment at an affordable price.
“Since our inception, neurodegenerative diseases have been on the list of indications we want to work on. “After a thorough analysis of the potential benefits of using psychedelic molecules to alleviate specific symptoms in Alzheimer’s patients, we are now able to address such indications.” We conclude that the best candidate from our portfolio is BMND08, an oral formulation of 5-MeO-DMT.”
Nearly 6 million older Americans are living with Alzheimer’s disease
Alzheimer’s disease is a progressive neurological disorder in which brain cells atrophy and die. In the United States, about 6 million people over the age of 65 are living with the disease. according to the information From Mayo Clinic. The disease is the most common cause of dementia, resulting in a continual decline in cognitive function and social skills, affecting the ability to function independently. There is no cure for Alzheimer’s disease, although medication can temporarily improve symptoms or slow progression. As the disease progresses, complications from dehydration, malnutrition, infections, and other serious loss of brain function can lead to death.
“Given the significant morbidity associated with Alzheimer’s disease, such as agitation, apathy, sleep disturbance, and anxiety, it has become clear that new approaches to treat Alzheimer’s-type cognitive impairment are urgently needed.” The Phase II clinical trial will test Biomind’s psychiatric intervention-based model, allowing rapid and viable integration of fast-acting psychedelic drugs into existing clinical practice.”
In this study, BMND08, a drug based on the natural psychedelic compound 5-Methoxy-N,N-dimethyltryptamine (also known as 5-MeO-DMT or simply DMT), was used to treat commonly seen depression. and whether it is effective as a therapeutic agent for anxiety neurosis. among Alzheimer’s disease patients. A Phase II clinical trial was conducted in Argentina, and regulators approved the trial in May.
Previous studies have shown that more than 60% of Alzheimer’s patients are diagnosed with depression. Treating depression in patients may also help treat or delay other symptoms associated with Alzheimer’s disease. An unrelated study showed that an antidepressant called imipramine may be effective in treating cognitive decline in patients with this condition. While there are studies that do research, the Biomind study is believed to be the first to test a psychedelic like DMT.
“Current clinical guidelines consistently refer to symptom management as central to the treatment of Alzheimer’s disease, but the lack of established effective treatments has motivated the creation of new treatments. ” said Antalich.